Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DTaP-IPV-HB-PRP~T combined vaccine · 1 trial · 7 indications
Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA
| Arm | Type | Description |
|---|---|---|
| Group 1 (the investigational group) | EXPERIMENTAL | Hexaxim at 2, 4 and 6 MoA |
| Group 2 (the comparator group) | ACTIVE_COMPARATOR | Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA |
| Name | Type | Description |
|---|---|---|
| DTaP-IPV-HB-PRP~T combined vaccine | BIOLOGICAL | Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection |
| DTaP-IPV//PRP~T combined vaccine | BIOLOGICAL | Pharmaceutical form:Freeze-dried PRP\~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection |
| monovalent Hep B vaccine | BIOLOGICAL | Pharmaceutical form: Depending on the brand procured Route of administration:IM injection |
Inclusion Criteria: * Aged 30 to 45 days on the day of inclusion, and have received 1 dose of monovalent Hep B vaccine * Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period above 28 (\>28 weeks) through 36 weeks with a birth weight ≥1.5 kg, an...